Chiroscience signs deal for asthma drug
Saturday 28 June 1997
The US group, regarded as number three in the treatment of respiratory diseases, will underwrite the research and development of Chiroscience's class of anti-inflammatory treatments known as PDE IV inhibitors, including what is being claimed as the leading treatment for asthma, codenamed D4418. In exchange, Schering will be given exclusive world-wide rights to any drugs which result from the research.
John Padfield, Chiroscience chief executive, said asthma was a growing problem, affecting some 14 per cent of the Western World's population. "To be working on our PDE IV inhibitors with a company of the calibre of Schering-Plough is exciting and acknowledges the success we have achieved to date with D4418 and other research compounds," he said.
Chiroscience estimates the Western market for asthma drugs is worth around $4bn, but claims that only half of all sufferers are treated due to difficulties in using treatments. Children, for instance, have problems using inhalers to take drugs such as Glaxo's Becotide, one of the leading treatments for asthma. Chiroscience's product will be in pill form. However, it is not expected to reach the market before 2003, even if it clears clinical trials currently under way in phase I.
Last year, Celltech, another biotech group, and Merck of the US abandoned development of a rival PDE IV-based product, codenamed CDP840. Chiroscience now reckons it has the lead in this class of drug, which it claims is the only one which attacks all four main components of asthma - wheezing at the beginning and after an attack and the associated inflammation and phlegm brought up from the stomach.
Other uses for the treatment being researched include chronic bronchitis, rheumatoid arthritis and the skin conditions atopic eczema and psoriasis.
The group will receive an initial licence fee, milestone payments and research and development finance under the Schering deal, with any royalty payments coming in on top of the initial $38m maximum.
Separately, Shire Pharmaceuticals, another biotech group, announced it had secured certain exclusive marketing rights to distribute Urispas, a urinary treatment, from Recordati of Italy.
Exclusive: World’s most pristine waters are polluted by US Navy human waste
Missing Malaysia Airlines Flight MH370: Any terrorist seizure of the plane ‘would have required one hell of a piece of planning’
Croatia's second city to close 'worst zoo in the world' after reports of 'nightmare' conditions and 'depressed' animals
Missing Malaysia Airlines Flight MH370: Hijackers, pirates or suicide – the theories surrounding the mystery
Missing Malaysia Airlines Flight MH370 Q&A by Simon Calder: How far could it have travelled? Who was responsible and what would their plans be? And how can a plane just vanish?
Katie Hopkins continues campaign to become Britain's most hated talking head with poorly timed Bob Crow tweet
No EU referendum under Labour: Ed Miliband to reveal that vote on membership is ‘unlikely’ in next Parliament if party wins power
Grace Dent: Who cares if she spells it Barraco Barner? Gemma Worrall is more employable than some bookish arts graduate
The rise of Ukip: Study warns Labour that Eurosceptic party's electoral base now 'more working class than any of the main parties'
Europeans have ‘got whiter’ due to natural selection in past 5,000 years, scientists say
Fracking is turning the US into a bigger oil producer than Saudi Arabia
- 1 Is your name now 'banned' in Saudi Arabia?
- 2 Exclusive: World’s most pristine waters are polluted by US Navy human waste
- 3 Gender-specific books demean all our children. So the Independent on Sunday will no longer review anything marketed to exclude either sex
- 4 Missing Malaysia Airlines Flight MH370: Jet ‘hijacking’ began soon after take-off
- 5 'Missing Malaysia Airlines Flight MH370 plane found in Bermuda Triangle!' Viral Facebook links are profiting hackers
iJobs Money & Business
£35000 - £43000 per annum + Bonus and Benefits: Harrington Starr: A global lea...
£50000 - £60000 per annum: Harrington Starr: Linux Systems Administrator - UNI...
£32000 - £36000 per annum + generous benefits: Pro-Recruitment Group: * TAX * ...
£37000 - £40000 per annum + £20000 benefits package: Pro-Recruitment Group: **...